

## DAFTAR PUSTAKA

- Agrawal, A., Shrive, A.K., Greenhough, T.J., Volanakis, J.E. 2001. Topology and structure of the C1q-binding site on C-reactive protein. *J Immunol*;166:3998-4004. 10.4049/jimmunol.166.6.3998
- Akchurin, M., & Kaskel, F. 2015. Update on Inflammation in Chronic Kidney Disease. *Blood Purification*, 39(1-3), 84-92. DOI: 10.1159/000368940.
- Ao, W., Gao, L., Wang, Y., & Chen, Z. 2021. Association between neutrophil-to-lymphocyte ratio and cardiovascular mortality in patients with chronic kidney disease: A cohort study. *Journal of Nephrology*. 34(2): 345-354. <https://doi.org/10.1007/s40620-021-00949-7>
- Axelsson, J., Carrero, J. J., Lindholm, B., Heimbürger, O., & Stenvinkel, P. 2007. Malnutrition in patients with end-stage renal disease: Anorexia, cachexia, and catabolism. *Current Nutrition & Food Science*.3(1): 37-46.
- B Braun. 2023. *DIACAP PRO Dialyzers - High-flux dialyzers for efficient hemodialysis treatment*. Retrieved from [www.bbraun.com](http://www.bbraun.com).
- Bacci, M. R., Saccardo Sarmiento, R., Nannini Grochoski, M., Leal, C., Cendoroglo, M. S., & Balbi, A. L. 2018. Inflammatory profile and quality of life in hemodialysis patients. *International Archives of Medicine*, 11, 1–7.
- Banait, T., Wanjari, A., Danade, V., Banait, S., Jain, J. 2022. Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review. *Cureus* ;14(10):e30225. doi: 10.7759/cureus.30225. PMID: 36381804; PMCID: PMC9650935.
- Baradari, A.G., Espahbodi, F., Aarabi, M. 2012. The effect of intravenous vitamin C on the phosphorus level reduction in hemodialysis patients: a double blind randomized clinical trial. *Med Glas (Zenica)*. 9(1):37-41. PMID: 22634906.
- Bassuk, S.S., Rifai, N., Ridker, P.M. 2004. High-sensitivity C-reactive protein: Clinical importance. *Curr. Probl. Cardiol*. 29: 439–493. doi:10.1016/j.cpcardiol.2004.03.004
- Biniaz, V., Sadeghi Shermeh, M., Ebadi, A., Tayebi, A., & Einollahi, B. 2014. Effect of vitamin C supplementation on C-reactive protein levels in hemodialysis patients: A randomized controlled trial. *Iranian Journal of Kidney Diseases*. 8(1):35–40.
- Carr, A. C., & Maggini, S. 2017. Vitamin C and immune function. *Nutrients*. 9(11):1211. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707683/>
- Biswas, S.K. 2016. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? *Oxid. Med. Cell. Longev*.5698931.
- Böhm, V., Tiroke, K., Schneider, S., Sperschneider, H., Stein, G., Bitsch, R. 1997. Vitamin C status of patients with chronic renal failure, dialysis patients and patients after renal transplantation. *Int J Vitam Nutr Res*. 67: 262-266 [PMID: 9285256]

- Bowie, A.G., O'Neill, L.A. 2000. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. *J. Immunol.*165, 7180–7188. [CrossRef] [PubMed]
- Bradbury, B. D., Critchlow, C. W., Weir, M. R., Stewart, R., Krishnan, M., & Hakim, R. H. 2009. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. *Nephrology Dialysis Transplantation.* 24(3):919–925.
- Braun Avitum AG. *Diacap Pro High Flux Technical Data Sheet.* Version 04/2017. Melsungen, Germany: B. Braun Avitum AG; 2017. Available from: <https://www.bbraun-dialysis.com>
- Caglar, K., Peng, Y., Pupim, L.B., Flakoll, P.J., Levenhagen, D., Hakim, R.M., *et al.*, 2002. Inflammatory signals associated with hemodialysis. *Kidney Int.* 62, 1408–1416.
- Canavese, C., Petrarulo, M., Massarenti, P., Berutti, S., Fenoglio, R., Pauletto, D., Lanfranco, G., Bergamo, D., Sandri, L., Marangella, M. 2005. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. *Am J Kidney Dis.* 45: 540-549 [PMID: 15754276].
- Carrero JJ, Stenvinkel P, Cuppari L, *et al.* 2013. Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). *J Ren Nutr.*23(2):77–90.
- Carrero, J.J., Stenvinkel, P. 2010. Inflammation in end-stage renal disease—What have we learned in 10 years? *Semin. Dial.*23, 498–509.
- Chaghouri, P., Maalouf, N., Peters, S.L., Nowak, P.J., Peczek, K., Zasowska-Nowak, A., Nowicki, M. 2021. Two Faces of Vitamin C in Hemodialysis Patients: Relation to Oxidative Stress and Inflammation. *Nutrients.* 13(3):791. doi: 10.3390/nu13030791. PMID: 33673687; PMCID: PMC7997461.
- Chan, D., Irish, A., Dogra, G. 2005. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. *Nephrology (Carlton).*10(4):336-40. doi: 10.1111/j.1440-1797.2005.00424.x. PMID: 16109077.
- Chazot C, Steiber A, Kopple JD. 2023. Vitamin Needs and Treatment for Chronic Kidney Disease Patients. *Journal of Renal Nutrition.*33(6S): S21–S29.
- Cheung, A.K., Sarnak, M.J., Yan, G., Berkoben, M., Heyka, R., Kaufman, A., *et al.*,2004. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int.* 65(6):2380–9. doi: 10.1111/j.1523-1755.2004.00657.x
- Cheung, A.K., Sarnak, M.J., Yan, G., *et al.* 2000. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney Int.* 58(1):353–362.
- Chien, C.T., Chang, W.T., Chen, H.W., Wang, T.D., Liou, S.Y., Chen, T.J., Chang, Y.L., Lee, Y.T., Hsu, S.M. 2004. Ascorbate supplement reduces oxidative

stress in dyslipidemic patients undergoing apheresis. *Arterioscler Thromb Vasc Biol.* 24(6):1111-7. doi: 10.1161/01.ATV.0000127620.12310.89. Epub 2004 . PMID: 15072991.

- Collins, A.J. 2003. Cardiovascular mortality in end-stage renal disease. *Am J Med Sci.* 325(4):163–167.
- Cozzolino, M., Mangano, M., Stucchi, A., Ciceri, P., Conte, F., Galassi, A. 2018 Cardiovascular disease in dialysis patients. *Nephrol Dial Transplant.* 33(suppl\_3):iii28–34. doi: 10.1093/ndt/gfy174
- Dahlan, S., 2016. Besar sampel dalam penelitian kedokteran dan kesehatan. *Epidemiologi Indonesia*, edisi 4. ISBN 978-602-18408-8-7
- Dai, L., Golembiewska, E., Lindholm, B., Stenvinkel, P., 2017. End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes. *Contrib. Nephrol.* 191: 32–43. doi:10.1159/000479254
- de Jager, D.J, Grootendorst, D.C., Jager, K.J., van Dijk, P.C., Tomas, L.M., Ansell, D., *et al.*, 2009. Cardiovascular and noncardiovascular mortality among patients starting dialysis. *Jama.* 302(16):1782–9. doi: 10.1001/jama.2009.1488
- Deicher, R., Ziai, F., Bieglmayer, C., Schillinger, M., Horl, W.H. 2005. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. *J. Am. Soc. Nephrol.* 16, 1811–1818. [CrossRef].
- Deicher, R., & Hörl, W. H. 2003. Vitamin C in chronic kidney disease and hemodialysis patients. *Kidney and Blood Pressure Research.* 26(2):100–106. <https://doi.org/10.1159/000070991>
- Descombes, E., Hanck, A.B., Fellay, G. 1993. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. *Kidney Int.* 43: 1319-1328 [PMID: 8315945]
- Deved, V., Poyah, P., James, M.T., Tonelli, M., Manns, B.J., Walsh, M.; *et al.*, 2009. Ascorbic acid for anemia management in hemodialysis patients: A systematic review and meta-analysis. *Am. J. Kidney Dis.* 54, 1089–1097.
- Dewi, A.M.P.I., 2013. Pengaruh vitamin C dan N-Asetil Sistein terhadap penurunan kadar IL-6 dan CRP pada pasien penyakit ginjal kronis stadium V yang menjalani hemodialisis di RSUD Moewardi Surakarta, tesis.
- Dominic, S., Raj., Roberto Pecoits-Filho., Paul, L., Kimmel., 2015. Chapter 17- Inflammation in Chronic Kidney Disease, Chronic Renal Disease, Academic Press, Pages 199-212, ISBN 9780124116023, <https://doi.org/10.1016/B978-0-12-411602-3.00017-2>.
- Dounousi, E., Papavasiliou, E., Makedou, A., Ioannou, K., Katopodis, K. P., Tselepis, A., Siamopoulos, K. C., & Tsakiris, D. 2006. Oxidative stress is progressively enhanced with advancing stages of CKD. *American Journal of Kidney Diseases.* 48(5), 7:52–760. <https://doi.org/10.1053/j.ajkd.2006.08.015>

- Dungey, M., Hull, K. L., Smith, A. C., Burton, J. O., & Bishop, N. C. 2013. Inflammatory factors and exercise in chronic kidney disease. *International Journal of Endocrinology*. (2013); 1-12.
- Echefu, G., Stowe, I., Burka, S., Basu-Ray, I., & Kumbala, D. 2023. Pathophysiological concepts and screening of cardiovascular disease in dialysis patients. *Frontiers in Nephrology*, 3, 1198560. <https://doi.org/10.3389/fneph.2023.1198560>
- Ehlerding, G., Erenkötter, A., Gaulty, A., Griesshaber, B., Kennedy, J., Rauber, L., Ries, W., Schmidt-Gürtler, H., Stauss-Grabo, M., Wagner, S., Zawada, A. M., Zschätzsch, S., & Kempkes-Koch, M. 2021. Performance and hemocompatibility of a novel polysulfone dialyzer: A randomized controlled trial. *Kidney360*. 2(6):937–947. <https://doi.org/10.34067/KID.0000302021>
- Eknoyan, G., Beck, G.J., Cheung, A.K., Daugirdas, J.T., Greene, T., Kusek, J.W., *et al.*, 2002. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med* .347(25):2010–9. doi: 10.1056/NEJMoa021583
- Ellulu, M. S., Rahmat, A., Patimah, I., Khaza'ai, H., & Abed, Y.2015. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: A randomized controlled trial. *Drug Design, DevelopmentandTherapy*. (9):3405–3412.
- Filiopoulos, V., Vlassopoulos, D. 2009. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. *Inflamm Allergy Drug Targets*. (5):369-82. doi: 10.2174/1871528110908050369. PMID: 20025585
- Fresenius Medical Care. *FX classix – Cardioprotective Haemodialysis: High-Flux Dialysis for Improved Survival* [Internet]. Bad Homburg, Germany: Fresenius Medical Care Deutschland GmbH; 2012. Available from: <https://www.fmc-ag.com>
- Fumeron, C., Nguyen-Khoa, T., Saltiel, C., Kebede, M., Buisson, C., Drüeke, T.B., *et al.*, 2005. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. *Nephrol Dial Transplant*. 9:1874-9. doi: 10.1093/ndt/gfh928. Epub 2005 Jun 21. PMID: 15972322.
- Gęgotek, A., Skrzydlewska, E. 2022. Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid. *Antioxidants (Basel)*.11(10):1993. doi: 10.3390/antiox11101993. PMID: 36290716; PMCID: PMC9598715.
- Gerster, H. 1999. High-dose vitamin C: A risk for persons with high iron stores? *International Journal for Vitamin and Nutrition Research*. 69(2) :67-74.
- Giancaspro, V., Nuzziello, M., Pallotta, G., Sacchetti, A., Petrarulo, F. 2000. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. *J Nephrol*. 13: 444-449 [PMID: 11132761]
- Handoko, A., Mahardhika, G. S., & Zain, H. 2022. *Potensi Candesartan dalam terapi COVID-19*. *Cermin Dunia Kedokteran*-301, 49(2): 102-107.
- Hanna RM, Ghobry L, Wassef O, Rhee CM, Kalantar-Zadeh K. 2020. A Practical Approach to Nutrition, Protein-Energy Wasting, Sarcopenia, and Cachexia in

- Patients with Chronic Kidney Disease. *Blood Purif.* 49(1-2):202-211. doi: 10.1159/000504240. Epub 2019 Dec 18. PMID: 31851983.
- Hastjarjo, T.D. 2019. Rancangan Eksperimen- Kuasi. *Buletin Psikologi.* 27(2): 187-203.
- Ikeda, U. 2003. Inflammation and coronary artery disease. *Curr Vasc Pharmacol.*1(1):65–70.
- Indonesian Renal Registry (IRR). 2018. 11<sup>th</sup> Report Of Indonesian Renal Registry. *Program Indonesia Renal Registry.* PERNEFRI
- Indonesian Renal Registry (IRR). 2020. 13<sup>th</sup> Report Of Indonesian Renal Registry. *Program Indonesia Renal Registry.* PERNEFRI
- Johnston, N., Dargie, H., Jardine, A. 2008. Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease: Ischemic heart disease. *Heart.* 94(8): 1080–1088.
- Juszczak, A.B., Kupczak, M., Konecki, T. 2023. Does Vitamin Supplementation Play a Role in Chronic Kidney Disease? *Nutrients.* 15(13):2847. doi: 10.3390/nu15132847. PMID: 37447174; PMCID: PMC10343669. Wijaya, I., Agustina. 2016 Peran Vitamin C pada Pasien Hemodialisis. *Cermin Dunia Kedokteran.* 239. Vol 43, no 4.
- Kalantar-Zadeh K, Rodríguez RA, Humphreys MH. 2004. Association between serum ferritin and measures of inflammation, nutrition, and iron status in hemodialysis patients. *Nephrol Dial Transplant.*19(1):141-149. doi:10.1093/ndt/gfg452.
- Kalantar-Zadeh, K., Braglia, A., Chow, J., Kwon, O., Kuwae, N., Colman, S., Cockram, D.B., Kopple, J.D. 2005. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. *J Ren Nutr.*15: 318-331 [PMID: 16007562]
- Kalantar-Zadeh, K., Ikizler, T.A., Block, G., Avram, M.M., Kopple, J.D.2003. Malnutrition-Inflammation Complex Syndrome in dialysis patients: causes and consequences. *Am. J. Kidney Dis.*, 42, 864-81.
- Kalantar-Zadeh, K., Stenvinkel, P., Pillon, L., Kopple, J.D. 2003. Inflammation and nutrition in renal insufficiency. *Adv Ren Replace Ther.* 3:155-69. doi: 10.1053/j.arrt.2003.08.008. PMID: 14708070.
- Kamgar, M., Zaldivar, F., Vaziri, N.D., Pahl, M.V.2009. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. *J Natl Med Assoc.*101(4):336-44. doi: 10.1016/s0027-9684(15)30881-6. PMID: 19397224.
- Kaysen, G. A., Dubin, J. A., Muller, H. G., Mitch, W. E., Rosales, L. M., & Levin, N. W. 2003. Relationships among inflammation, nutrition, and albumin levels in hemodialysis patients. *Kidney International.* 61:2240–2249.
- Keller, T. 2014. Re: Is there any way to get mean and SD from median and IQR (interquartile range)? Retrieved [https://www.researchgate.net/post/Is there any way to get mean and SD](https://www.researchgate.net/post/Is_there_any_way_to_get_mean_and_SD)

[from median and IQR interquartile range/53296a11d11b8bce568b45f7/citation/download.](http://etd.repository.ugm.ac.id/53296a11d11b8bce568b45f7/citation/download)

- Kendrick, J., Chonchol, M.B. 2008. Non-traditional risk factors for cardiovascular disease in patients with chronic kidney disease. *Nat. Clin. Pract. Nephrol.*,4, 672-81.
- Keven, K., Kutlay, S., Nergizoglu, G., Ertürk, S. 2003. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. *Am J Kidney Dis.* 41: 1233-1239 [PMID: 12776276]
- Khajehdehi, P.2000. Effect of vitamins on the lipid profile of patients on regular hemodialysis. *Scand J Urol Nephrol.*34: 62-66 [PMID: 10757273]
- Lagrand, W.K., Niessen, H.W., Wolbink, G.J., *et al.* 1997. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. *Circulation.*95:97-103. 10.1161/01.cir.95.1.97
- Latini, R., Maggioni, A.P., Peri, G., *et al.* 2004. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. *Circulation.*110(16):2349–2354
- Lau, W.L., Kalantar-Zadeh, K., Vaziri, N.D. 2015. The gut as a source of inflammation in chronic kidney disease. *Nephron.*130, 92–98.
- Libetta, C., Sepe, V., Esposito, P., Galli, F., Dal Canton, A. 2011. Oxidative stress and inflammation: Implications in uremia and hemodialysis. *Clin. Biochem.* 44, 1189–1198.
- Lloyd-Jones, D.M., Liu, K., Tian, L., Greenland, P. 2006. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. *Ann Intern Med.* 145:35-42. 10.7326/0003-4819-145-1-200607040-00129
- Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R. 2009. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. *J Am Soc Nephrol.* 20(3):645-54. doi: 10.1681/ASN.2008060590. PMID: 19092122; PMCID: PMC2653681.
- Locatelli, F., Canaud, B., Eckardt, K.U., Stenvinkel, P., Wanner, C., Zoccali, C. 2003. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrol. Dial. Transplant.* 18, 1272-80.
- Lowrie, E. G., & Lew, N. L. 1990. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *American Journal of Kidney Diseases.*15:458–482.
- Luan, Y.Y., Yao, Y.M. 2018. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. *Front Immunol.*9:1302. 10.3389/fimmu.2018.01302
- Lykkesfeldt, J., & Tveden-Nyborg, P. 2019. The pharmacokinetics of vitamin C. *Nutrients.*11(10):2412. <https://doi.org/10.3390/nu11102412>

- Machowska, A., Carrero, J.J., Lindholm, B., Stenvinkel, P. 2016. Therapeutics targeting persistent inflammation in chronic kidney disease. *Transl. Res.*167, 204–213.
- Morena, M., Cristol, J.P., Bosc, J.Y., Tetta, C., Forret, G., Leger, C.L., Delcourt, C., Papoz, L., Descomps, B., Canaud, B. 2002. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. *Nephrol Dial Transplant* .17: 422-427 [PMID: 11865087]
- Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, et al. 2004. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Report from the laboratory science discussion group. *Circulation*.110(25):e545-e549.doi: 10.1161/01.CIR.0000148980.87579.5E.
- National Kidney Foundation. 2024. Can you eat high potassium fruits and vegetables on a low-potassium diet? [Internet]. New York: National Kidney Foundation; [cited 2025 Apr 28]. Available from: <https://www.kidney.org/atoz/content/potassium>
- Nowak, K.L., Chonchol, M. 2018. Does inflammation affect outcomes in dialysis patients? *Semin Dial*. 31(4):388-397. doi: 10.1111/sdi.12686. Epub 2018 Mar 7. PMID: 29513906; PMCID: PMC6035073.
- Ohno, S., et al. 2018. High-dose vitamin C therapy for patients with cancer. *Anticancer Research*, 38(3):1633-1638.
- Omar, S., El Borolossy, R.M., Elsaid, T., Sabri, N.A. 2022. Evaluation of the combination effect of rutin and vitamin C supplementation on the oxidative stress and inflammation in hemodialysis patients. *Front. Pharmacol*. 13: 1–12. doi:10.3389/fphar.2022.961590
- Padayatty, S. J., & Levine, M. 2016. Vitamin C: The known and the unknown and Goldilocks. *Oral Diseases*. <https://doi.org/10.1111/odi.12446>
- Padayatty, S. J., et al. 2003. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. *J. Am. Coll. Nutr*. 22(1):18-35.
- Panichi, V., Migliori, M., De Pietro S., et al. 2001. C reactive protein in patients with chronic renal disease. *Renal Failure*. 23:551-62.
- Pearson, T.A., Mensah, G.A., Alexander, R.W., et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*; 107:499-511.10.1161/01.cir.0000052939.59093.45
- Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S. 2004. Association of Obesity With Inflammation in Chronic Kidney Disease: A Cross-Sectional Study. *J Ren Nutr*. 14(4):201-207. doi:10.1053/j.jrn.2004.07.009.
- Ramón R, Holguín E, Chiriboga JD, Rubio N, Ballesteros C, Ezechieli M. 2023. Anti-Inflammatory Effect of Vitamin C during the Postoperative Period in Patients Subjected to Total Knee Arthroplasty: A Randomized Controlled Trial. *J Pers*

*Med.*13(9):1299. doi: 10.3390/jpm13091299. PMID: 37763067; PMCID: PMC10532858.

- Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S. 2019. Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. *Int J Mol Sci.*21(1):263. doi: 10.3390/ijms21010263. PMID: 31906008; PMCID: PMC6981831.
- Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation.* 98:31–733.
- Ronco, C., *et al.* 2017. Expanded hemodialysis: from operational mechanism to clinical results. *Nephrology Dialysis Transplantation.* 32(suppl\_2): ii5-ii11.
- Sabatino, A., Regolisti, G., Brusasco, I., Cabassi, A., Morabito, S., Fiaccadori, E. 2015. Alterations of intestinal barrier and microbiota in chronic kidney disease. *Nephrol. Dial. Transplant.* 30, 924–933.
- Sabatino, A., Regolisti, G., Karupaiah, T., Sahathevan, S., Sadu Singh, B.K., Khor, B.H., *et al.*, 2017. Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. *Clin. Nutr.*36, 663–671.
- Sachdeva, M., Hung, A., Kovalchuk, O., Bitzer, M., Mokrzycki, M.H. 2012. The initial vascular access type contributes to inflammation in incident hemodialysis patients. *Int. J. Nephrol.*2012, 917465.
- Salazar, J., Martínez, M.S., Chávez-Castillo, M., *et al.* 2014. C-reactive protein: an in-depth look into structure, function, and regulation. *Int Sch Res Notices.*2014:653045. 10.1155/2014/653045
- Sanz, A.B., Sanchez-Nino, M.D., Ramos, A.M., Moreno, J.A., Santamaria, B., Ruiz-Ortega, *et al.*, 2010. Nf-kappab in renal inflammation. *J. Am. Soc. Nephrol.* 21, 1254–1262.
- Saran, R., Robinson, B., Abbott, K.C. 2017. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis.* 69:A7–A8. [PubMed: 28236831]
- Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culeton, B., Hamm, L.L., *et al.*,2003. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Hypertension.* 42(5):1050–65. doi: 10.1161/01.HYP.0000102971.85504.7c
- Sato, M., Matsumoto, Y., Morita, H., Takemura, H., Shimoi, K., Amano, I. 2003. Effects of vitamin supplementation on microcirculatory disturbance in hemodialysis patients without peripheral arterial disease. *Clin Nephrol.* 60: 28-34 [PMID: 12872855]

- Soeters, P. B., Wolfe, R. R., & Shenkin, A. 2019. Hypoalbuminemia: Pathogenesis and clinical significance. *Journal of Parenteral and Enteral Nutrition*, 43(2), 181–193.
- Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, et al. 2002. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? *Kidney Int.*62(5):1791-8. doi:10.1046/j.1523-1755.2002.00623.x.
- Stenvinkel, P. 2006. Inflammation in end-stage renal disease: The hidden enemy. *Nephrology*.11, 36–41. Stenvinkel, P. 2010. Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. *J Intern Med.* 268(5):456-467.
- Stenvinkel, P. 2006. New insights on inflammation in chronic kidney disease – Genetic and non-genetic factors. *Nephrologie & Thérapeutique*, 2(2), 111–119.
- Stenvinkel, P., Carrero, J.J., Axelsson, J., Lindholm, B., Heimbürger, O., Massy, Z. 2008. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? *Clin J Am Soc Nephrol.* 3(2): 505–521.
- Stenvinkel, P., Ketteler, M., Johnson, R.J., et al. 2005. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. *Kidney Int.* 67(4):1216–1233.
- Sugiyono. 2017. Metode penelitian kuantitatif, kualitatif, dan R&D. Bandung: CV Alfabeta.
- Susantitaphong, P., Riella, C., Jaber, B.L. 2013. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: A meta-analysis. *Nephrol. Dial. Transplant.* 28, 438–446.
- Tang Y, Jiang J, Zhao Y, Du D. 2024. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity. *Clin Kidney J.* 17(9):sfac235. doi:10.1093/ckj/sfac235.
- Tarnag, D.C., Wei, Y.H., Huang, T.P., Kuo, B.I., Yang, W.C. 1999. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. *Kidney Int.* 55: 2477-2486 [PMID: 10354297]
- Tonelli, M., Wiebe, N., Cullerton, B., House, A., Rabbat, C., Fok, M., et al., 2006. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol.* 17(7):2034–47. doi: 10.1681/ASN.2005101085
- United States Renal Data System. 2017. USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States; National Institutes of Health: Bethesda, MD, USA; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA.
- United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Available at: <https://adr.usrds.org/2022>.
- Valga F, Monzón T, Vega-Diaz N, Rodriguez-Perez JC, Ruiz-Santana S. 2021. Inflamación y adecuación de la hemodiálisis: ¿están los niveles de proteína C

reactiva influidos por la dosis de diálisis recibida? *Nefrologia*. doi:10.1016/j.nefro.2021.06.001.

- Vlagopoulos, P.T., Sarnak, M.J. 2005. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. *Med Clin North Am*.89(3):587-611. doi: 10.1016/j.mcna.2004.11.003. PMID: 15755469.
- Wang, A.Y., Elsurer Afsar, R., Sussman-Dabach, E.J, White, J.A., MacLaughlin, H., Ikizler, T.A. 2024. Vitamin Supplement Use in Patients With CKD: Worth the Pill Burden? *Am J Kidney Dis*.83(3):370-385. doi: 10.1053/j.ajkd.2023.09.005. Epub 2023 Oct 24. PMID: 37879527.
- Wang, Y., Gao, L. 2022. Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease. *Front Pharmacol*.13:800950. doi: 10.3389/fphar.2022.800950. PMID: 35222026; PMCID: PMC8867697.
- Wei, H., Ren J, Li., R, Qi, X., Yang, F., Li Q. 2024. Global, regional, and national burden of chronic kidney disease attributable to high fasting plasma glucose from 1990 to 2019: a systematic analysis from the global burden of disease study 2019. *Front Endocrinol (Lausanne)*.15:1379634. doi: 10.3389/fendo.2024.1379634. PMID: 38601204; PMCID: PMC11004380.
- Wulandari, D.C., Suwitra, K. 2012. Pengaruh Terhadap C-Reactive Protein Sebagai Petanda Inflamasi Pada Gagal Ginjal Kronik Dengan Hemodialisis Reguler. *Journal of internal medicine*. Available at: <https://jurnal.harianregional.com/jim/id-3866>.
- Yeun, J. Y., Levine, R. A., Mantadilok, V., & Kaysen, G. A. 2000. C-reactive protein supersedes albumin in predicting mortality in hemodialysis patients. *American Journal of Kidney Diseases*. 35:469–476.
- Zhang, K. Y., & Zuo, L. (2014). Vitamin C supplementation in patients on maintenance dialysis. *World J Clin Urol*. 3(3):344-350. DOI: 10.5410/wjcu.v3.i3.344.
- Zhang, K., Li ,Y., Cheng, X., Liu, L., Bai, W., Guo, W., Wu, L., Zuo, L. 2013. Cross-over study of influence of oral vitamin C supplementation on inflammatory status in maintenance hemodialysis patients. *BMC Nephrol*. 14: 252 [PMID: 24228847 DOI: 10.1186/1471-2369-14-252]
- Zhang, K., Liu, L., Cheng, X., Dong, J., Geng, Q., Zuo, L. 2011. Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein. *BMC Nephrol*.12, 18.
- Zhao, W., Wu, Y., Xu, L., Zhang, H., Yin, T., Tang, Y., & Wang, L. 2020. Neutrophil-to-lymphocyte ratio as a predictor of all-cause mortality and cardiovascular events in patients with chronic kidney disease: A systematic review and meta-analysis. *BMC Nephrology*. 21(1): 1-10.
- Zoccali, C., 2000. Cardiovascular risk in uraemic patients – is it fully explained by classical risk factors? *Nephrol. Dial. Transplant*. 15:454-7.
- Zoccali, C., Mallamaci, F., Tripepi, G. 2004. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. *Nephrol. Dial. Transplant*., 19 (Suppl 5), 67-72.